medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 2

<< Back Next >>

Rev Invest Clin 2009; 61 (2)

Anticoncepción en pacientes con lupus eritematoso generalizado

Cravioto MC, Durand-Carbajal M, Sánchez-Guerrero J

Language: Spanish
References: 47
Page: 150-160
PDF size: 143.76 Kb.


Text Extraction

No abstract


REFERENCES

  1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of SLEDAI. A disease activity index for lupus patients. The Committee of prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-40.

  2. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682-8.

  3. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34: 1538-45.

  4. Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133-8.

  5. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum 1993; 36: 1392-7.

  6. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 514-21.

  7. Carmona F, Font J, Cervera R , Muñoz F, Cararach V, Balasch J. Obstetrical outcome of pregnancy in patients with systemic lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol 1999; 83: 137-42.

  8. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Torres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002; 41: 643-50.

  9. Medical eligibility criteria for contraceptive use. 3rd. Ed. Geneva: World Health Organization, 2004. (http://www.who.int/ reproductive-health/publications).

  10. Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008; 17: 412-5.

  11. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-23.

  12. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20: 427-33.

  13. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza- Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2539-49.

  14. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8.

  15. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35.

  16. Romero-Díaz J, García-Sosa I, Sánchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2008; Nov 15, publicación electrónica.

  17. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-6.

  18. Sarabi ZS, Chang E, Bobba R, Ibanez D, Gladman D, Urowitz M, et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005; 53: 609-12.

  19. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14-8.

  20. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997; 6: 467-73.

  21. Chopra N, Koren S, Greer WL, Fortin PR, Rauch J, Fortin I, et al. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 2002; 29: 1683-8.

  22. Choojitarom K, Verasertniyom O, Totemchokchyakarn K, Nantiruj K, Sumethkul V, Janwityanujit S. Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 2008; 27: 345-51.

  23. Clowse MEB, Jamison M, Myers E, James AH. A national study of the complications of lupus pregnancy. Am J Obstet Gynecol 2008; 199: 127.e1-e6.

  24. McDonald J, Stewart J, Urowitz MB, Gladman DD. Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 56-60.

  25. McAlindon T, Giannotta L, Taub N, D’Cruz D, Hughes G. Environmental factors predicting nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 720-4.

  26. Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan R, et al. Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 1178-81.

  27. Bernatsky S, Ramsey-Goldman R, Gordon C, Joseph L, Boivin JF, Rajan R, et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 1386-9.

  28. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 882-90.

  29. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995; 8: 137-45.

  30. Mintz G, Gutierrez G, Deleze M, Rodríguez E. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984; 30: 29-38.

  31. Petri M. The Hopkins Lupus Pregnancy Center: Ten key issues in management. Rheum Dis Clin North Am 2007; 33: 227-35.

  32. Walsh JS, Eastell R, Peel NF. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab 2008; 93: 1317-23.

  33. Cromer BA, Bonny AE, Stager M, Lazebnik R, Rome E, Ziegler J, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008; 90: 2060-7.

  34. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women with systemic lupus erythematosus. Br J Rheumatol 1993; 32: 227-30.

  35. Selected Practice Recommendations for contraceptive use. 2nd. Ed. Geneva: World Health Organization, 2004. (http:// www.who.int/reproductive-health/publications).

  36. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), INFO Project. Family Planning: A global handbook for providers. Baltimore and Geneva: CCP and WHO, 2007. (http://www.who.int/reproductive-health/ publications).

  37. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006; 15: 877-80.

  38. Medical eligibility criteria for contraceptive use. 4th. edition. Geneva: World Health Organization, En prensa. (http:// www.who.int/reproductive-health/publications).

  39. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 863-6.

  40. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza- Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. New Engl J Med 2005; 353: 2539-49.

  41. Invernizzi P, Miozzo M, Oertelt-Prigione S, Meroni PL, Persani L, Selmi C, et al. X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1110: 84-91.

  42. Invernizzi P, Miozzo M, Selmi C, Persani L, Battezzati PM, Zuin M, et al. X chromosome monosomy: a common mechanism for autoinmune diseases. J Immunol 2005; 175: 575-8.

  43. Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, et al.. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618-23.

  44. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. Scand J Rheumatol 1991; 20: 427-33.

  45. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 863-6.

  46. Sánchez Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Menopause hormonal therapy in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 3070-9.

  47. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn NH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953-62.




2020     |     www.medigraphic.com